What question did this study set out to answer?

The research aims to identify cGAS-STING activation markers and their influence on IBD treatment responses.

P0124cGAS-STING in Inflammatory Bowel Disease—and repression by SCFAs through a HDAC-mediated mechanism

View Full Paper

Ask AI

Bookmark

Authors

Uncovers cGAS-STING's role in inflammation in IBD, highlighting butyrate's potential therapeutic effects.

The research aims to identify cGAS-STING activation markers and their influence on IBD treatment responses.
Stratification of IBD patient cohorts by therapy response
Proteomic analysis of plasma samples for cGAS-STING markers
In-vitro assays using macrophages with STING agonists and butyrate
Western Blot analysis for phosphorylation of TBK1 and IRF3
RT-PCR and ELISA for interferon and chemokine quantification
Increased plasma levels of IFN-β and other markers in non-responders to therapy
Macrophages showed significant upregulation of IFN-β and CXCL10 following STING activation
Butyrate repressed secretion of IFN-β and CXCL10 in macrophage models
HDAC inhibitors mirrored the effects of butyrate, indicating similar suppression mechanisms

Mahony et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark